Skip to main content
Figure 4 | Journal of Neuroinflammation

Figure 4

From: Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis

Figure 4

Diazoxide treatment improves clinical signs in the EAE model. Animals were orally administered with 0.8 mg/kg diazoxide or vehicle (0.3% DMSO in water) at the onset of clinical signs (day 10-13 post immunization) (Score ≥ 1). Once the treatment started the animals were orally treated for 15 days. A minimum of 7 mice per group was used in each experiment. Data show the mean of three independent experiments (A) and AUC for each clinical score curve (B). Diazoxide treatment was also tested for 30 days by starting its administration on the same day as that of the MOG35-55 immunization. Data show the daily score mean (C) and the AUC for each clinical score curve (D). Data are represented as mean ± SEM. * p < 0.05, ** p < 0.01.

Back to article page